{"id":"bupropion-extra-long-xl","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Insomnia"},{"rate":"17-24%","effect":"Dry mouth"},{"rate":"8-13%","effect":"Nausea"},{"rate":"26%","effect":"Headache"},{"rate":"6-11%","effect":"Dizziness"},{"rate":"5-10%","effect":"Constipation"},{"rate":"0.4%","effect":"Seizures (dose-dependent)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The XL formulation provides extended-release delivery for once-daily dosing, maintaining therapeutic levels throughout the day.","oneSentence":"Bupropion XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:20.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT00519428","phase":"PHASE4","title":"Does Dual Therapy Hasten Antidepressant Response?","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-08","conditions":"Major Depressive Disorder","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Wellbutrin extra long (XL)"],"phase":"marketed","status":"active","brandName":"bupropion extra long (XL)","genericName":"bupropion extra long (XL)","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion extra long (XL) is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that is classified as a dopamine transporter inhibitor. It has been studied as a treatment for Major Depressive Disorder, often in combination with other antidepressants such as escitalopram.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}